Association Between the CEP72 Genotype and Chemotherapy-Induced Peripheral Neuropathy Severity in Young Adults Receiving Vincristine or Paclitaxel
Oncology Nursing Forum · 2025
DOI: 10.1188/25.onf.323-329 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Nursing Forum, 2025. Verfasst von Robert Knoerl und 10 weiteren Autor:innen. Beteiligte Einrichtung: Robert Knoerl. Hauptthemen laut MEDLINE: Paclitaxel, Vincristine, Peripheral Nervous System Diseases, Neoplasms. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINR NIH HHS, NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
OBJECTIVES: To determine the relationship between chemotherapy-induced peripheral neuropathy (CIPN) severity and centrosomal protein 72 (CEP72) genotype in young adults receiving paclitaxel or vincristine. SAMPLE & SETTING: 50 young adults aged 21-39 years who were expected to receive a cumulative dose of at least 7 mg vincristine or 700 mg/m2 paclitaxel for the treatment of cancer were recruited from Dana-Farber Cancer Institute. METHODS & VARIABLES: Participants completed a CIPN assessment tool and provided a blood sample before the first infusion. Participants completed the assessment tool at two additional time points. DNA was genotyped for CEP72 rs924607. CIPN scores were compared between those with the TT versus the CC or CT genotype over time using linear mixed-effects models. RESULTS: Young adults receiving vincristine with the TT CEP72 genotype experienced higher CIPN severity by the final time point, but the differences were not statistically significant (p > 0.05). IMPLICATIONS FOR NURSING: Future work to validate biomarkers like CEP72 may allow clinicians to identify patients who may benefit from altered chemotherapy dosages relative to CIPN risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Robert Knoerl.
- Emanuele Mazzola.
- Maria F. Pazyra-Murphy.
- Lindsay Frazier.
- Roy Freeman.
- Marilyn J. Hammer.
Förderung
- NINR NIH HHS
- NCI NIH HHS
Zitieren
APA
Knoerl, R., Mazzola, E., Pazyra-Murphy, M. F., Frazier, L., Freeman, R., Hammer, M. J., LaCasce, A. S., Ligibel, J., Luskin, M. R., Berry, D. L., & Segal, R. A. (2025). Association Between the CEP72 Genotype and Chemotherapy-Induced Peripheral Neuropathy Severity in Young Adults Receiving Vincristine or Paclitaxel. Oncology Nursing Forum. https://doi.org/10.1188/25.onf.323-329
Vancouver
Knoerl R, Mazzola E, Pazyra-Murphy MF, Frazier L, Freeman R, Hammer MJ, et al. Association Between the CEP72 Genotype and Chemotherapy-Induced Peripheral Neuropathy Severity in Young Adults Receiving Vincristine or Paclitaxel. Oncology Nursing Forum. 2025. doi:10.1188/25.onf.323-329
BibTeX
@article{Knoerl2025,
author = {Knoerl, Robert and Mazzola, Emanuele and Pazyra-Murphy, Maria F and Frazier, Lindsay and Freeman, Roy and Hammer, Marilyn J and LaCasce, Ann S and Ligibel, Jennifer and Luskin, Marlise R and Berry, Donna L and Segal, Rosalind A},
title = {Association Between the CEP72 Genotype and Chemotherapy-Induced Peripheral Neuropathy Severity in Young Adults Receiving Vincristine or Paclitaxel},
journal = {Oncology Nursing Forum},
year = {2025},
doi = {10.1188/25.onf.323-329}
}
EUVIMED